Article Per Year (5 Year)
p-Index From 2021 - 2026
4.761
P-Index
This Author published in this journals
All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Jurnal Riset Farmasi Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Folia Medica Indonesiana
Didik Hasmono
Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 74 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 74 Documents
Search

 2   3   4   5   6 
Studi Penggunaan Carboplatin untuk Penderita Kanker Payudara di RUMKITAL Dr. Ramelan Surabaya Alfin Giovani; Didik Hasmono; Siti Surdijati; Joko Semedi
Jurnal Farmasi Sains dan Terapan Vol 7, No 1 (2020): Februari
Publisher : Jurnal Farmasi Sains dan Terapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (237.919 KB) | DOI: 10.33508/jfst.v7i2.2393

Abstract

Cancer is an abnormal growth of new cells that grow beyond normal limits. Cancer can metastasize by attacking parts of the body and spread to other organs. The prevalence of cancer Indonesian’s people in 2013 is estimated at 347,792. Breast cancer is the most common cancer in women with a percentage of 23%. Breast cancer is the second most common cancer with death after cervical cancer. Breast cancer is divided according to histologic subtype to Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). Carboplatin is a platinum analog cancer drug that belongs to the class of antineoplastic agents. Carboplatin doses used in AUC 6 (i.v) breast cancer chemotherapy for 1 cycle with 21 days to 6 cycle times. This research was conducted observasional with descriptive research design and retrospective data retrieval. The purpose of this study was to know the profile of carboplatin as an anti-cancer drug that is expected to provide safe treatment. This research was conducted at Dr. RUMKITAL Ramelan Surabaya with the number of inclusion of 30 patients in the period January 1, 2017 - December 31, 2017. From the results of this study obtained the use of single carboplatin as much as 7% and a combination of 93%. Patients with chemotherapy administered without surgery and surgery were 73% and 27%, respectively. Toxicity of nausea and vomiting happen as much as 42% and pain as much as 19%.
The Use of Diuretics on Hepatic Cirrhosis Patient with Ascites Didik Hasmono
Journal of Global Pharma Technology Volume 11 Issue 6.
Publisher : Journal of Global Pharma Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (391.694 KB)

Abstract

Background: Hepatic cirrhosis with ascites complication increases the mortality up to 50% in a matter of years. Diuretics are a class of drugs that are often used as choices. The pattern of diuretics use of hepatic cirrhosis patient with ascites in the hospital needs to be studied further because if the use is not appropriate, it will potentially lead to drug related problems that affect patient management. Aim: to examine the pattern of diuretics use of hepatic cirrhosis patient with ascites which undergoing treatment in the hospital inpatient unit. Method: a descriptive and retrospective study using medical records. Criteria for inclusion of the sample were (1) Hepatic cirrhosis patient with ascites complication (2) Age> 20 years (3) Receive diuretic therapy (4) Complete medical record. The exclusion criteria were patient who was hospitalized for less than 3 days. Study samples were recorded on the data collection sheet. Sampling with time limited sampling method. Result: The total number of patients who met the inclusion criteria was 45 patients. The diuretics which most used was furosemide, both in single doses and in combination with Spironolactone. The hepatic cirrhosis patient with ascites in this study not only received diuretic therapy, but patient also received other drugs that used to prevent and overcome complication. In drug interaction, the potential use of Spironolactone with Potassium (KCl or KSR) preparation increases the risk of hyperkalemia. Conclusion: Most of the diuretic therapies obtained by hepatic cirrhosis patient with those who were hospitalized which have been in accordance with the available guidelines.Keywords: As cites, Drug Related Problems, Diuretics, Hepatic Cirrhosis.
Antibiotic Use Evaluation in ICU/HCU of Muhammadiyah University General Hospital Malang using DDD and Gyssens Methods Hidajah Rachmawati; Muktamiroh Muktamiroh; Didik Hasmono; Atika Putri Kusumaningtyas; Sendi Lia Yunita; Lilik Yusetyani
Jurnal Kedokteran Brawijaya Vol. 32 No. 3 (2023)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2023.032.03.7

Abstract

Infection is a condition caused by the propagation of harmful microorganisms with or without clinical symptoms. Improper use of antibiotics can lead to antibiotic resistance. The Ministry of Health of the Republic of Indonesia recommended a quantitative evaluation of the use of antibiotics using the Defined Daily Dose (DDD) method and a qualitative evaluation using the Gyssens method. This study evaluated antibiotics usage using DDD and Gyssens methods in ICU/HCU of the Muhammadiyah University General Hospital Malang. Employing retrospective observational method, data were collected from patient medical records hospitalized during January-December 2020. Results of the DDD quantitative analysis showed that the most widely used antibiotic was Ceftriaxone with a 35.79 DDD/100 patient-days. The Gyssenss qualitative analysis showed that the category VI (incomplete patient's medical record data) was 3%, category IVa (antibiotic use is more effective) (2%), category IIIb (duration of antibiotic use is too short) (3%), category IIb (antibiotic use is not at the right interval) (3%).
STUDI PENGGUNAAN LOPINAVIR/RITONAVIR PADA PASIEN COVID-19 DERAJAT RINGAN-SEDANG DENGAN KOMORBID HIPERTENSI DAN DIABETES MELLITUS Didik Hasmono; Agriawan Sudirman; Muhammad Nashrullah; Ruddy Hartono; Mohammad Subhan
Jurnal Kesehatan Vol 16 No 1 (2023): JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v16i1.28711

Abstract

Lopinavir/Ritonavir is proposed as one of the therapy for Covid-19 patients based on the ability to reduce viral load. Bhayangkara Hospital Surabaya is one of the hospitals with quite a lot of Covid-19 patients in Surabaya. The research aimed to determine the effectiveness, outcome, and evaluate side effects of Lopinavir/Ritonavir in mild to moderate Covid-19 patients with comorbid hypertension and diabetes mellitus at Bhayangkara Hospital Surabaya. This was an observational study that collected data retrospectively at Bhayangkara Hospital Surabaya. Patient data had to meet the requirements for inclusion criteria, which were patients treated with Lopinavir/Ritonavir for a Covid-19 mild to moderate with comorbid hypertension and diabetes mellitus. Data were obtained from 18 patient medical records and then processed descriptively. The results showed that 7 patients (39%) received therapy A with 11 days of treatment, 4 patients received therapy B (22%) with 12 days of treatment, 1 patient (11%) received therapy C with 18 days of treatment, and 6 patients (28%) on D therapy with 14 days of treatment. Patients experiencing effects of gastrointestinal disturbances such as nausea (22%), and diarrhea (11%). Lopinavir/Ritonavir in therapy A is the most effective when viewed from the length of treatment, which is 11 days. Therapy B, C, and D were considered effective as seen from the results of RT-PCR which showed negative results, namely 100%. Therapy D is the most effective chest X-ray repair, which is 50%. Side effects of Lopinavir/Ritonavir were gastrointestinal disturbances, namely nausea (22%), and diarrhea (11%), while hepatotoxicity was not found.
Studi Penggunaan Asam Traneksamat pada Pasien BPH dengan Operasi Transurethral Resection of The Prostate Irsan Fahmi Almuhtarihan; Aghnia Fuadatul Inayah; Didik Hasmono; Hendra Yadi
Jurnal Ilmiah Farmasi Farmasyifa Vol 6, No 2 (2023)
Publisher : Universitas Islam Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29313/jiff.v6i2.10547

Abstract

Latar Belakang: Benign Prostatic Hyperplasia (BPH) merupakan kondisi ketika sel-sel prostat mengalami peningkatan pertumbuhan akibat sel stroma dan epitel yang terus mengalami proliferasi. BPH sering dialami oleh laki-laki usia >50 tahun dan biasanya disertai dengan gejala lower urinary tract symptoms (LUTS). Manajemen terapi pada BPH meliputi watchful waiting, terapi farmakologi dan tindakan pembedahan. Tindakan pembedahan termasuk penyelesaian gejala jangka panjang paling baik pada BPH. Transurethral Resection of The Prostate (TURP) adalah tindakan paling umum dilakukan dengan komplikasi utama adalah perdarahan. Asam traneksamat termasuk antifibrinolitik dan merupakan inhibitor kuat terhadap plasminogen dan urokinase. Obat ini bekerja dengan menghambat interaksi plasminogen dengan fibrin sehingga dapat mencegah fibrinolisis.Tujuan: Penelitian ini bertujuan untuk mengetahui pola penggunaan asam traneksamat pada pasien Benign Prostatic Hyperplasia di Rumah Sakit Umum Daerah Kabupaten Kediri.Metode: Penelitian dilakukan secara observasional dengan metode retrospektif pada pasien Benign Prostatic Hyperplasia di Rumah Sakit Umum Daerah Kabupaten Kediri periode Januari 2019 - November 2019.Hasil dan Kesimpulan: Pola penggunaan asam traneksamat hanya digunakan tunggal pada 40 pasien (100%) dengan regimentasi dosis paling banyak digunakan adalah (3x500mg) IV sebanyak 24 pasien (60%) dan lama terapi paling banyak diberikan sekitar 2-8 hari sebanyak 39 pasien (98%).
Studi Penggunaan Antihipertensi Golongan Angiotensin Reseptor Blocker (ARB) pada Pasien Chronic Kidney Disease (Penelitian dilakukan di RS Universitas Muhammadiyah Malang) Nurfausiah, Nurfausiah; Hasmono, Didik; Kusumaningtyas, Atika Putri; Syifa', Nailis
JFM (Jurnal Farmasi Malahayati) Vol 7, No 2 (2024)
Publisher : Jurnal Farmasi Malahayati (JFM)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/jfm.v7i2.15903

Abstract

Hypertension and chronic kidney disease (CKD) are interrelated pathophysiological conditions, where sustained hypertension can lead the deterioration of renal function, and progressive deterioration of renal function can conversely result in poorer blood pressure (BP) control. Antihypertensives are given to CKD patients with the goal of lowering their blood pressure to < 140 mmHg and preventing harm to other organs. Angiotensin Receptor Blockers (ARB) are one of the first line of therapy used to reduce blood pressure in CKD patients. The research purpose was to determine the pattern of ARB regarding the type, dosage form, combination, and route of the group given to CKD patients at UMM’s General Hospital. Research was conducted in observational research with a descriptive nature and retrospective data collection on the health medical record of CKD with period January – Desember 2022. Results of the research showed that patients who met the inclusion criteria amounted to 25 patients using ARB antihypertensive therapy, the highest number of gender 52% male and 48% female, at the age of 46-55 years. The most common single use was Candesartan (1x16mg)po (5%) 2 patients, the most common combination II was Candesartan (1x16mg)po + Furosemide (3x40mg) iv 7 patients (18%), the most common combination III was Candesartan (1x16mg)po + Amlodipine (1x10mg)v + Furosemide (3x40mg)iv, the most common combination IV was Candesartan (1x16mg)po + Amlodipine (1x10mg)po + Clonidine (3x0.15mg)po + Furosemide (3x40mg)iv. There was a switch pattern as many as 13 samples (52%). Most patients met the blood pressure target at ≤ 140 mmHg.
Studi pola administrasi penggunaan asetosal pada pasien stroke iskemik Almuhtarihan, Irsan Fahmi; Irianto, Jimmy Setiawan; Hasmono, Didik; Syifa, Nailis'
Pharmasipha : Pharmaceutical Journal of Islamic Pharmacy Vol. 8 No. 1 (2024): Maret
Publisher : University Of Darussalam Gontor

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21111/pharmasipha.v8i1.11623

Abstract

Stroke iskemik disebabkan oleh peristiwa trombotik atau emboli yang menyempitkan arteri sehingga menyebabkan penurunan aliran darah ke otak. Oleh karena itu, terapi antiplatelet digunakan untuk menghambat pembentukan tromboksan. Asetosal dianggap sebagai antiplatet lini pertama dan efektivitasnya sudah diketahui dengan baik, namun masih terdapat kebingungan dalam praktik klinis mengenai dosis optimal untuk pencegahan dan pengobatan stroke. Penelitian ini bertujuan untuk mengetahui pola pemberian asetosal pada pasien stroke iskemik di RSUD dr. RSUD Moh Saleh Probolinggo. Penelitian ini bersifat observasional dengan metode retrospektif pada pasien stroke iskemik pada bulan Januari 2021 sampai dengan Desember 2021. Asetosal digunakan sendiri pada semua pasien (20 pasien). Semua pasien diberikan asetosal 1x80 mg p.o. Peralihan terapi dari clopidogrel (1x75 mg) p.o ke acetosal (1x80 mg) p.o. ditemukan pada satu sampel.
The Effectiveness Of Atorvastatin On Kidney Function In Outpatient Diabetic Nephrophaty Patients Hasmono, Didik; Tanasy, Marledy; Firandi, Adelia; Hartono, Ruddy; Hanum, Putri Safitri
Pharmaceutical Journal of Indonesia Vol. 9 No. 1 (2023)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2023.009.01.1

Abstract

Introduction: Dyslipidemia can damage the kidneys through increased oxidative stress. Statins can be used as adjunctive therapy to standard treatment with ACEIs or ARBs to improve renoprotection. Objective: The study is that to analyze the effectiveness atorvastatin on changes in kidney function in patients diabetic nephropathy. Methods: It was observational study. Samples were taken prospectively from diabetic nephropathy patients receiving atorvastatin at the Interna Polyclinic of the Bhayangkara Hospital Surabaya namely November 2021 – January 2022. Patients aged 18 – 80 years received atorvastatin for ≤3 months before the study was conducted, with GFR stages 3A, 3B, and 4, with mild, moderate, and severe albuminuria degrees. Results: There are several patients which receive ARBs, namely candesartan and ketoacid which can affect the results of the analysis so that different tests are conducted in the three groups, the result shows a significant decrease in BUN values in the sample group which receives additional ketoacid therapy (p <0.05); besides, a decrease in parameters albuminuria in the group with additional 16 mg candesartan therapy which is not significant. Conclusion: The administration atorvastatin alone 20 mg or in combination with candesartan 16 mg and ketoacid on kidney function after 3 months of use can prevent the progression of diabetic nephropathy. Key words: Atorvastatin; Diabetic Nephropathy; Kidney Function
The Effectiveness Of Atorvastatin On Kidney Function In Outpatient Diabetic Nephrophaty Patients Hasmono, Didik; Tanasy, Marledy; Firandi, Adelia; Hartono, Ruddy; Hanum, Putri Safitri
Pharmaceutical Journal of Indonesia Vol. 9 No. 1 (2023)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2023.009.01.1

Abstract

Introduction: Dyslipidemia can damage the kidneys through increased oxidative stress. Statins can be used as adjunctive therapy to standard treatment with ACEIs or ARBs to improve renoprotection. Objective: The study is that to analyze the effectiveness atorvastatin on changes in kidney function in patients diabetic nephropathy. Methods: It was observational study. Samples were taken prospectively from diabetic nephropathy patients receiving atorvastatin at the Interna Polyclinic of the Bhayangkara Hospital Surabaya namely November 2021 – January 2022. Patients aged 18 – 80 years received atorvastatin for ≤3 months before the study was conducted, with GFR stages 3A, 3B, and 4, with mild, moderate, and severe albuminuria degrees. Results: There are several patients which receive ARBs, namely candesartan and ketoacid which can affect the results of the analysis so that different tests are conducted in the three groups, the result shows a significant decrease in BUN values in the sample group which receives additional ketoacid therapy (p <0.05); besides, a decrease in parameters albuminuria in the group with additional 16 mg candesartan therapy which is not significant. Conclusion: The administration atorvastatin alone 20 mg or in combination with candesartan 16 mg and ketoacid on kidney function after 3 months of use can prevent the progression of diabetic nephropathy. Key words: Atorvastatin; Diabetic Nephropathy; Kidney Function
STUDI PENGGUNAAN DEKSAMETASON PADA PASIEN COVID-19 DERAJAT BERAT DENGAN KOMORBID DIABETES MELLITUS Hasmono, Didik; As-Shiddiq, Hasbi; Insyirah Idris, Anissah; Agriawan Sudirman; Hartono, Ruddy; Subhan, Mohammad
Jurnal Kesehatan Vol 16 No 2 (2023): : JURNAL KESEHATAN
Publisher : Universitas Islam Negeri Alauddin Makassar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24252/kesehatan.v16i2.28712

Abstract

Administration of Dexamethasone in patients with diabetes needs attention because corticosteroids can increase blood glucose concentrations. Therefore, this study aims to determine the effectiveness of using Dexamethasone in patients with severe COVID-19 and how to regulate blood glucose in patients with severe COVID-19 in patients with comorbid Diabetes Mellitus. Inclusion criteria for severe COVID-19 patients with comorbid Diabetes Mellitus who use Dexamethasone and therapy groups and receive insulin therapy with or without OAD in inpatient installations. The sample data obtained from the patient's medical records were 27 patients who met the inclusion and exclusion criteria consisting of 70% male and 30% female. Dexamethasone dose of 1 x 6 mg iv mostly uses combination therapy A, the duration of administration is 8 days, and has an average length of stay of 13 days. The shortest average length of hospitalization was 12 days for patients receiving dexamethasone with therapy C for 10 days, while therapy B for 5 days had an average hospitalization of 14 days. Administration of Dexamethasone dose of 1 x 6 mg iv is effective in severe COVID-19 patients with comorbid Diabetes Mellitus based on the length of hospitalization, respectively 13 days, 14 days, and 12 days with an improvement in the clinical condition of oxygen saturation by 91%, 100%, 100%; RT-PCR/Rapid Ag became negative 74%, 100%, 100%; improvement of chest x-ray results, namely 83%, 33%, 100%. The effect of glucocorticoid dexamethasone in comorbid Diabetes Mellitus patients is regulated by administering long-acting insulin, rapid-acting insulin, and oral anti-diabetic.
Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Amanda, Anita Tria Amarullah, Adinugraha Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Badriyah, Rani Nur Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hadiyanti, Nur Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningrum , Yunita Dyah Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Ma'rifah, Nurul Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Saiful Islam, Mohammad Saiful Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Muzayyanah, Binti Nadriatul Utami Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Subagyo, Roni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Trengginas, Ganesha T Ugrasena, IGD Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Wisudani, Nuraida Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani Yulistiani, Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka